In patient-derived glioma stem cells (GSCs), Olig2 knockdown suppresses PDGFRA, while Olig2 silencing induces transcriptional reprogramming across GSC lines—transitioning from proneural to classical GBM expression patterns or proneural-to-mesenchymal transformation—with context-dependent regulation of EGFR expression by Olig2 [20]. The gene discussed is OLIG2; the disease is central nervous system cancer.